Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

osimertinib

Drug and asset intelligence for osimertinib with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

AstraZeneca →

Recent signals(3)

ClinicalJuly 29, 2026

Phase II/III Trial of BL-B01D1 with Osimertinib in EGFR-mutant NSCLC Initiated

A Phase II/III trial has been initiated to evaluate BL-B01D1 combined with osimertinib in patients with resectable EGFR-mutant non-small cell lung cancer.

ClinicalJuly 12, 2026

Phase II Trial of Osimertinib for NSCLC with EGFR Exon 20 Mutations

A phase II trial is underway to evaluate the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.

ClinicalJune 17, 2026

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

A phase III trial is comparing osimertinib alone versus its combination with bevacizumab in patients with EGFR-mutant non-small cell lung cancer.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Osimertinib

July 12, 2026 · N/A

Topline Data

AstraZeneca — Osimertinib

June 17, 2026 · N/A

Indications

Therapeutic areas

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.